2018
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study
Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser C, Fassò M, O’Hear C, Vogelzang NJ. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. JAMA Oncology 2018, 4: 537-544. PMID: 29423515, PMCID: PMC5885219, DOI: 10.1001/jamaoncol.2017.5440.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCarcinoma, Transitional CellCohort StudiesDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm MetastasisSurvival AnalysisTime FactorsUrinary Bladder NeoplasmsUrotheliumConceptsDeath ligand 1 (PD-L1) expressionMedian overall survivalMetastatic urothelial carcinomaLigand 1 expressionProgression-free survivalPhase 1 studyOverall survivalAdverse eventsClinical benefitUrothelial carcinomaImmune cellsEastern Cooperative Oncology Group performance status 0Long-term clinical profilesMedian progression-free survivalSerious related adverse eventsSolid Tumors version 1.1Treatment-related adverse eventsLong-term clinical outcomesTumor-infiltrating immune cellsPerformance status 0Treatment-related deathsUnacceptable toxic effectsMetastatic urothelial cancerObjective response rateThird-line therapy
2015
Emerging immunotherapies for bladder cancer
Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Current Opinion In Oncology 2015, 27: 191-200. PMID: 25811346, PMCID: PMC7709951, DOI: 10.1097/cco.0000000000000177.Peer-Reviewed Original ResearchConceptsUrothelial carcinomaImmune escapeImmune systemTumor antigen presentationAdvanced urothelial carcinomaBenefit of immunotherapyImmune escape mechanismsFraction of patientsHigh mutational burdenImmune-mediated cytotoxicityMultiple tumor typesDurable responsesImmune checkpointsBladder cancerClinical trialsT cellsCombinatorial regimensTumor antigensMutational burdenImmunotherapyClinical developmentCarcinomaTumor typesTumor cellsEscape mechanisms
2014
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046).
Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly K, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046). Urologic Oncology Seminars And Original Investigations 2014, 32: 637-644. PMID: 24840869, PMCID: PMC6771274, DOI: 10.1016/j.urolonc.2013.12.012.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerTreatment of MIBCUpper tract urothelial carcinomaNeoadjuvant chemotherapyMedical oncologistsUrothelial carcinomaBladder cancerEastern Cooperative Oncology Group performance statusHigh grade upper tract urothelial carcinomaBladder Cancer Advocacy NetworkUse of NACDose-dense methotrexateGemcitabine/carboplatinGemcitabine/cisplatinGlomerular filtration rateAdjuvant chemotherapyPerioperative chemotherapyChemotherapy regimensLymphovascular invasionPerformance statusT2 lesionsStandardization of practiceMost referralsFiltration rateChemotherapy management